QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 brainsway-awarded-25m-grant-from-us-nih-to-support-clinical-trial-evaluating-deep-transcranial-magnetic-stimulation-protocol-through-brainsways-device-for-alcohol-use-disorder-treatment

BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasiv...

 brainsway-announces-strategic-investment-in-heading-health-commits-up-to-4m-to-expand-mental-health-clinic-network

Recent agreements with two additional U.S. mental health providers bring total to four in 2025Strategy seeks to drive long-term...

 hc-wainwright--co-reiterates-buy-on-brainsway-maintains-17-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BrainsWay (NASDAQ:BWAY) with a Buy and maintains $17 price tar...

 brainsway-announces-strategic-investment-in-neurolief-ahead-of-fda-approval-and-commercial-launch-of-proliv-rx-for-major-depressive-disorder

 Neurolief, a pioneering brain stimulation company specializing in non-invasive neuromodulation therapies, today announced a st...

 brainsway-invests-23m-in-axis-mental-health-clinics-with-option-for-1m-more

BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasiv...

 northland-capital-markets-maintains-outperform-on-brainsway-raises-price-target-to-19

Northland Capital Markets analyst Carl Byrnes maintains BrainsWay (NASDAQ:BWAY) with a Outperform and raises the price targe...

 hc-wainwright--co-maintains-buy-on-brainsway-raises-price-target-to-17

HC Wainwright & Co. analyst Raghuram Selvaraju maintains BrainsWay (NASDAQ:BWAY) with a Buy and raises the price target ...

 brainsway-raises-fy2025-sales-guidance-from-49000m-51000m-to-50000m-52000m

BrainsWay (NASDAQ:BWAY) raises FY2025 sales outlook from $49.000 million-$51.000 million to $50.000 million-$52.000 million.

 brainsway-q2-eps-005-inline-sales-12632m-beat-12357m-estimate

BrainsWay (NASDAQ:BWAY) reported quarterly earnings of $0.05 per share which met the analyst consensus estimate. This is a 150 ...

 hc-wainwright--co-reiterates-buy-on-brainsway-maintains-16-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BrainsWay (NASDAQ:BWAY) with a Buy and maintains $16 price tar...

 hc-wainwright--co-reiterates-buy-on-brainsway-maintains-16-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BrainsWay (NASDAQ:BWAY) with a Buy and maintains $16 price tar...

 brainsway-enters-into-strategic-equity-financing-agreement-with-stella-mso-to-invest-5m-in-stella

BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasiv...

 brainsway-affirms-fy2025-sales-guidance-of-4900m-5100m-vs-17975m-est

BrainsWay (NASDAQ:BWAY) affirms FY2025 sales outlook from $49.00 million-$51.00 million to $49.00 million-$51.00 million vs $17...

 brainsway-q1-eps-002-misses-009-estimate-sales-1154m-miss-4139m-estimate

BrainsWay (NASDAQ:BWAY) reported quarterly earnings of $0.02 per share which missed the analyst consensus estimate of $0.09 by ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION